Gunnar B. Kristensen

发表

Lack of independent prognostic significance of p21 and p27 expression in advanced ovarian cancer: an immunohistochemical study.

J. Nesland, J. Nesland, R. Holm, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials.

G. Kenter, M. Nankivell, S. Kehoe, 2018, The Lancet. Oncology.

Are borderline tumors of the ovary overtreated both surgically and systemically? A review of four prospective randomized trials including 253 patients with borderline tumors.

V. Abeler, I. Vergote, C. Tropé, 1993, Gynecologic oncology.

Expression of membrane-type 1, 2, and 3 matrix metalloproteinases messenger RNA in ovarian carcinoma cells in serous effusions.

J. Nesland, A. Berner, B. Davidson, 2001, American journal of clinical pathology.

Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument

V. Abeler, E. Pettersen, C. Tropé, 2000, International Journal of Gynecologic Cancer.

P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer.

J. Nesland, R. Holm, C. Tropé, 2000, Anticancer research.

Markers of apoptosis in stage IB squamous cervical carcinoma

R. Holm, G. van de Putte, A. Lie, 2005, Journal of Clinical Pathology.

First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)--a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG.

E. Eisenhauer, I. Vergote, G. Kristensen, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Large-scale genomic instability predicts long-term outcome for women with invasive stage I ovarian cancer.

I Vergote, H E Danielsen, V. Abeler, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Aberrant expression of the cell cycle associated proteins TP53, MDM2, p21, p27, cdk4, cyclin D1, RB, and EGFR in cervical carcinomas.

H. Skomedal, R. Holm, A. Lie, 1999, Gynecologic oncology.

Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions.

J. Nesland, A. Berner, B. Davidson, 2000, Human pathology.

Evaluation of Prognostic and Predictive Significance of Circulating MicroRNAs in Ovarian Cancer Patients

P. Beale, G. Kristensen, Å. Helland, 2017, Disease markers.